Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst
In-line quarter with single-digit profit growth; no guidance change. ESOP grant routine.
— 2 earlier stories on Vimta Labs Ltd. →What's new
- Revenue up 12% YoY to ₹1,090.74 million; PAT up 11% to ₹210.42 million.
- Auditors issued unmodified limited review report.
- Board approved 40,500 stock options under ESOP plan.
Why this matters
The quarter continues Vimta's steady run but offers no new catalyst. With no guidance revision or strategic announcement, the stock's 34.5x trailing P/E leaves little room for error if growth falters.
What we're watching
- Whether revenue growth accelerates from the current 12% pace.
- Any large contract wins in the CRO testing space.
- ESOP dilution impact, though 40,500 options are immaterial.
The full read
Vimta Labs' Q1 FY27 numbers are textbook continuation: revenue of ₹1,090.74 million up 12% year-on-year, profit of ₹210.42 million up 11%. The auditor signed off without modification, and the board handed out 40,500 stock options, too small to move the needle on a ₹2,671 cr market cap. The analyst call is routine, in-line, no guidance, no surprise. That is the problem. At 34.5x trailing earnings, the market is paying for acceleration. Vimta delivered consistency. Consistency alone rarely justifies the multiple.
Questions answered
- How did Vimta's Q1 results compare to expectations?
- Revenue growth of 12% and PAT growth of 11% are broadly in line with the company's recent trajectory, not a significant deviation from market expectations.
- What is the significance of the ESOP grant?
- The 40,500 options are a routine employee incentive grant, not material to earnings or dilution given a market cap of ₹2,671 cr.
- What is Vimta's core business?
- The company operates a single segment of contract research and testing services (CRO) for pharmaceuticals and other industries.
- Is the stock expensive at current levels?
- With a trailing P/E of 34.5x, the stock trades at a premium even for steady single-digit growth. Any slowdown could compress the multiple.
- Did the company provide any forward guidance?
- No. The filing contained only the financial results and ESOP approval, with no management commentary or updated outlook.
Vimta Labs Ltd.
Latest quarter · Dec 2024
Strength & growth
Story so far
All notes on VIMTALABS →- 20 Jul 2026 · 1:44 PM IST Vimta Labs Q1: Revenue up 12%, PAT up 11% — steady but not a catalyst
- 2d ago Vimta Labs lands first biologics order, budgets ₹80 cr capex for FY27
- 2d ago Vimta Labs Q1 revenue up 13.7%, EBITDA margin at 36.4%